REGENXBIO Inc. (RGNX) Wednesday reported additional positive results from the Phase I/II AFFINITY DUCHENNE trial of RGX-202 in patients with Duchenne muscular dystrophy.
The Phase I/II AFFINITY DUCHENNE trial is designed to evaluate the safety, tolerability and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in patients with Duchenne.
As per new data, a patient aged 6.6 years old, who received RGX-202 at dose level 1, had microdystrophin expression level at 83.4% of control at three months. A reduction from baseline in serum creatinine kinase (CK) levels of 93% was observed at ten weeks.
The company said it is on track to initiate pivotal trial in second half of 2024.
REGENXBIO shares are up more than 14% in pre-market. The stock had closed at $13.05, up 5.93% on Tuesday. It has traded in the range of $11.83 - $25.32 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.